ImmunoTargets and Therapy
Volume 3, 2014 - Issue
Open access
81
Views
2
CrossRef citations to date
0
Altmetric
Review
Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?
Diana L Castillo-Carranza1 Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX, USA;2 Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX, USA
, Marcos J Guerrero-Muñoz1 Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX, USA;2 Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX, USA
& Rakez Kayed1 Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX, USA;2 Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX, USA;3 Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USACorrespondence[email protected]
Pages 19-28
|
Published online: 27 Dec 2013
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.